(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Fundamental Home Items Each Animal person Needs - 2Step by step instructions to Show Children the Significance of Appropriate Handshaking
- 3PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- 4The Main 20 Gaming Control center Ever
- 5Greece eyes migrant repatriation centres outside the EU
- 4 Energy-Proficient Clothes washers to Consider in 2024
- ‘We are the alternative’: Anti-Hamas Gaza militia tells BBC group is receiving international support
- Most loved Web-based feature: Which Stage Do You Like
- Monetary Freedom Guide: Plan Your Future
- Find the Advantages of Innovative Leisure activities: Supporting Creative mind and Self-Articulation
- How a cocktail of rogue storms and climate chaos unleashed deadly flooding across Asia
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- How Google, Microsoft, Walmart, and other corporate giants are preparing for an aging workforce
- Astronomers detect black hole blasting winds at incredible speeds
